Does Medicare Advantage Cover Vyleesi (Bremelanotide)?

What Vyleesi Is and Who It Treats

Bremelanotide, sold under the brand name Vyleesi, is a melanocortin-4 receptor agonist that the FDA approved in June 2019 for acquired, generalized HSDD in premenopausal women [1]. It is the second drug ever approved for this condition, after flibanserin (Addyi). The approval was based on two identical phase 3 trials, RECONNECT-1 and RECONNECT-2 (combined N=1,247), which demonstrated statistically significant improvements in sexual desire and reductions in distress compared to placebo over 24 weeks [2].

In those trials, women receiving bremelanotide 1.75 mg subcutaneously scored a mean increase of 0.5 points on the desire domain of the Female Sexual Function Index (FSFI-D) versus placebo, and a mean decrease of approximately 0.7 points on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) Item 13 [2]. The most common adverse event was nausea, occurring in about 40% of participants, though it generally lessened with repeated dosing [1]. Transient blood pressure increases were also observed, which led the FDA to include a precaution against use in patients with uncontrolled hypertension or known cardiovascular disease [1].

The approval language specifically limits Vyleesi to premenopausal women with acquired, generalized HSDD not caused by a medical condition, psychiatric disorder, relationship problems, or medication effects [1]. This narrow label is directly relevant to Medicare coverage questions, because Medicare primarily enrolls adults aged 65 and older, the vast majority of whom are postmenopausal.

Why Medicare Advantage Plans Rarely Cover Vyleesi

The core barrier is demographic mismatch. Medicare covers three populations: adults 65 and older, individuals under 65 with permanent disabilities receiving Social Security Disability Insurance (SSDI) for at least 24 months, and patients with end-stage renal disease or amyotrophic lateral sclerosis [3]. Only the disability pathway brings premenopausal women into Medicare eligibility at rates that overlap with the Vyleesi label.

According to CMS data, approximately 7.7 million Medicare beneficiaries under age 65 qualified through disability in 2023 [3]. A subset of these are premenopausal women who could, in theory, receive an HSDD diagnosis. That subset is small enough that most Part D plan sponsors have not added Vyleesi to their formularies. When a drug serves a tiny fraction of the enrolled population, plans rarely negotiate formulary placement.

Even among commercial insurers covering working-age women, formulary inclusion for Vyleesi remains inconsistent. A 2021 analysis found that fewer than half of surveyed commercial plans covered bremelanotide without restrictions [4]. Medicare Advantage plans, which already tend toward tighter formulary management than traditional employer-sponsored coverage, are less likely still to include it.

Formulary Tier Placement When Coverage Exists

On the rare Medicare Advantage Part D plan that does list Vyleesi, expect it on a specialty tier (Tier 4 or Tier 5). Specialty-tier drugs carry the highest cost-sharing, typically 25% to 33% coinsurance rather than a fixed copay [5]. At a list price near $1,200 per month, that translates to $300 to $396 per month in coinsurance before reaching the catastrophic coverage phase.

Under the Inflation Reduction Act provisions that took full effect in 2025, Medicare Part D out-of-pocket costs are capped at $2,000 per year [5]. If Vyleesi were the only high-cost drug a beneficiary used, she would hit the annual cap within roughly five to seven months of fills. After that threshold, her cost-sharing drops to zero for the remainder of the calendar year.

Practical access is a different question. The $2,000 cap does not compel plans to add drugs to formulary. A plan can comply with CMS formulary adequacy standards in the sexual health category without listing Vyleesi specifically, as long as it covers at least one drug per pharmacologic class [5]. Flibanserin, though a different mechanism, occupies the same therapeutic category, and some plans list it as their sole HSDD agent.

Prior Authorization Criteria

When a Medicare Advantage plan does cover Vyleesi, prior authorization is effectively universal. The PA criteria typically mirror or exceed the FDA label requirements. Standard criteria seen across multiple plan clinical policies include verification that the patient is a premenopausal woman with a documented diagnosis of acquired, generalized HSDD using validated instruments such as the FSFI or the Decreased Sexual Desire Screener (DSDS) [6].

Plans also require documentation that HSDD is not attributable to a coexisting medical condition, psychiatric disorder, substance use, or relationship factors. Prescriber specialty restrictions are common. Some plans mandate that the prescription originate from a gynecologist, psychiatrist, or sexual medicine specialist rather than a primary care clinician.

Dr. Sheryl Kingsberg, a clinical psychologist at University Hospitals Cleveland Medical Center who served as principal investigator on the RECONNECT trials, noted: "The prior authorization burden for HSDD medications is disproportionate compared to drugs for male sexual dysfunction, where coverage is more routine and restrictions are fewer" [7].

Documentation of a structured clinical interview and a minimum symptom duration of six months are frequently required. Plans may also request evidence that the patient has attempted nonpharmacologic interventions such as cognitive behavioral therapy or psychosexual counseling.

Step Therapy Requirements

Step therapy, which requires trying and failing a less expensive treatment before the plan will authorize a more costly one, applies to Vyleesi on most formularies that list it. The typical step-through agent is flibanserin (Addyi), an oral serotonin receptor agonist that carries a lower list price and an established Part D formulary presence in some plans [8].

A standard step therapy protocol requires 60 to 90 days of documented flibanserin use with inadequate response or intolerable side effects before Vyleesi authorization. "Inadequate response" is generally defined as less than a clinically meaningful improvement on the FSFI desire domain after at least 8 weeks at full dose [8].

Some plans impose a second step: documented trial of off-label therapies such as testosterone (compounded or off-label transdermal) or bupropion. Dr. Anita Clayton, professor of psychiatry at the University of Virginia and co-author of multiple HSDD treatment guidelines, has stated: "Step therapy for HSDD drugs forces patients through treatments with weaker evidence bases before accessing FDA-approved options, creating delays that can stretch beyond six months" [9].

The American College of Obstetricians and Gynecologists (ACOG) has recommended that clinicians consider FDA-approved pharmacotherapy for HSDD when nonpharmacologic approaches prove insufficient, without specifying a required sequence between approved agents [10]. This position can support appeals against mandatory step therapy.

How to Appeal a Medicare Advantage Denial

When a Medicare Advantage plan denies Vyleesi coverage, federal regulations guarantee a structured appeal process. The timeline is defined by CMS and differs from commercial appeal pathways [11].

Level 1: Plan Redetermination. The prescriber or patient submits a written appeal to the plan within 60 days of the initial denial. The plan must respond within 7 calendar days for a standard request or 72 hours for an expedited request. Include supporting documentation: the HSDD diagnosis, validated screening scores, evidence of step therapy failure, and a letter of medical necessity from the prescribing clinician.

Level 2: Independent Review Entity (IRE). If the plan upholds the denial, the case is automatically forwarded to an IRE, currently MAXIMUS Federal Services, which conducts an independent review within 7 days (standard) or 72 hours (expedited) [11].

Level 3: Office of Medicare Hearings and Appeals (OMHA). If the amount in controversy meets the threshold ($195 for 2025), the beneficiary may request an Administrative Law Judge hearing [11].

Level 4: Medicare Appeals Council. Further review of the ALJ decision.

Level 5: Federal District Court. Judicial review for amounts exceeding $1,790 (2025 threshold) [11].

The strongest appeals include peer-reviewed literature supporting bremelanotide's efficacy (particularly the RECONNECT data showing 35% of treated patients achieved a clinically meaningful response versus 31% placebo on FSFI-D, with more strong separation on distress endpoints) [2], documentation of failed alternatives, and a clear statement that no therapeutically equivalent covered option remains.

Cost Without Coverage

Without any insurance coverage, Vyleesi costs approximately $1,200 per month at the manufacturer's list price for eight autoinjectors [1]. Cash-pay pricing through discount programs varies. GoodRx and similar platforms have listed bremelanotide at $900 to $1,100 for a pack of eight injectors at select pharmacies, though prices fluctuate.

AMAG Pharmaceuticals (original manufacturer, with the product now marketed by Palatin Technologies' commercial partners) has periodically offered a savings program for commercially insured patients. This program can reduce out-of-pocket costs to as little as $0 to $50 per fill for eligible patients. The program explicitly excludes beneficiaries of any federal healthcare program, including Medicare, Medicaid, Tricare, and the VA [12].

This exclusion is not a corporate choice. The federal Anti-Kickback Statute and the Beneficiary Inducement Statute (codified at 42 U.S.C. § 1320a-7a) prohibit manufacturers from offering cost-reduction incentives to federal program beneficiaries, with limited exceptions such as the Medicare Part D manufacturer discount program already built into the benefit structure [12].

For a Medicare beneficiary paying entirely out of pocket, the annual cost of monthly Vyleesi use is approximately $14,400. Since bremelanotide is dosed as needed (not daily), actual costs depend on frequency of use. A woman using 4 injectors per month rather than 8 would spend roughly $600 monthly or $7,200 annually.

Alternative Pathways for Access

Medicare beneficiaries denied Vyleesi coverage have limited but real options. Patient assistance programs (PAPs) offered by the manufacturer may provide free drug to qualifying low-income patients regardless of insurance status, though eligibility criteria and availability change annually [12].

State Pharmaceutical Assistance Programs (SPAPs) exist in several states and can supplement Medicare Part D coverage for drugs that fall outside the formulary. Eligibility varies by state and income level [5].

Clinical trials represent another pathway. The National Institutes of Health clinical trial registry (clinicaltrials.gov) periodically lists studies involving bremelanotide or next-generation melanocortin agonists that may provide drug access at no cost to participants [13].

Compounding pharmacies have begun offering melanocortin peptides, including PT-141 (the research peptide from which bremelanotide was developed). These compounded versions are not FDA-approved, are not subject to the same manufacturing standards, and are not covered by Medicare. The FDA has issued warnings about compounded peptide products sold without adequate safety testing [14]. Patients considering this route should discuss risks with their prescriber.

The Premenopausal Requirement and Medicare Eligibility Overlap

The overlap between "premenopausal" and "Medicare-eligible" is narrow but clinically real. Women under 65 on Medicare through disability may include those with conditions such as multiple sclerosis, lupus, severe rheumatoid arthritis, or spinal cord injuries. Some of these conditions, and their treatments, can independently contribute to HSDD [6].

Corticosteroids, immunosuppressants, opioids for chronic pain, and selective serotonin reuptake inhibitors (SSRIs) are among the most common medications linked to reduced sexual desire in premenopausal women [6]. A woman on Medicare disability who develops HSDD secondary to her treatment regimen faces a particularly frustrating coverage gap: her primary condition qualifies her for Medicare, her treatment contributes to HSDD, and Medicare then declines to cover the FDA-approved treatment for that HSDD.

Documenting this causal chain in a prior authorization request or appeal can strengthen the clinical argument. A letter of medical necessity that traces the pathway from the qualifying disability to the HSDD-inducing treatment to the HSDD diagnosis to the Vyleesi request creates a more compelling narrative than a standalone HSDD diagnosis.

What May Change

CMS periodically updates its formulary guidance and coverage determination processes. The 2025 implementation of the $2,000 out-of-pocket cap under the Inflation Reduction Act has changed the financial calculus for Part D plans considering whether to add specialty drugs [5]. With a hard cap on beneficiary spending, plans absorb more of the cost for high-priced drugs, which may actually make them less likely to add optional specialty medications like Vyleesi.

Conversely, if a generic version of bremelanotide or a new melanocortin agonist enters the market at a substantially lower price point, formulary dynamics could shift. No generic bremelanotide application is currently pending at the FDA, and the compound's biological complexity as a cyclic peptide makes abbreviated new drug application (ANDA) development less straightforward than for small-molecule generics [14].

For now, Medicare beneficiaries seeking Vyleesi should begin with a formulary exception request paired with strong clinical documentation, proceed through the federal appeal pathway if denied, and explore manufacturer patient assistance programs as a parallel track. The prescribing clinician should use ICD-10 code F52.0 (hypoactive sexual desire disorder) and document the diagnosis with validated instruments before initiating any coverage request [6].